News

The financing was led by individual investors including Carl Lombardi, former CEO of SpaceLabs Medical and Sam Naficy, medical director of Naficy Plastic Surgery & Rejuvenation Center. The

Under the agreement, Elekta will share identified sales opportunities for the Xoft Axxent Electronic Brachytherapy in the radiation oncology market. This non-exclusive agreement allows Elekta to expand its

Applying its expertise in medicinal and synthetic chemistry, ChemDiv will support Achaogen in identifying and developing novel antibacterial compounds. Heinz Moser, senior vice president for chemistry at Achaogen,

Teva is currently involved in patent litigation with Wyeth concerning this product in the US District Court of New Jersey. In September 2007, the district court denied a

This study builds on prior pharmacodynamic and safety data in a three-day study of TPI ASM8 in an allergen challenge model and will be conducted in collaboration with

Aggrastat is indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and who are undergoing percutaneous transluminal coronary angioplasty. Outside of

The Phase I proof-of-concept trial is being conducted at a single center with approximately 30 healthy male volunteers and is designed to determine the safety, tolerability and pharmacokinetics

The primary objectives of the study are to determine the dose-limiting toxicity and maximum tolerated dose of AFP-464 in patients with advanced solid tumors. The trial is expected

The Fast Track drug development program is designed to promote the development of drugs to treat life-threatening or very serious conditions and requires that the drug demonstrate the